Computerized molecular docking assays were conducted to assess the roles of hydroxychloroquine (HCQ) and chloroquine (CQ) in preventative or therapeutic care of COVID-19. Studies analyzed these drug interactions with SARS-CoV-2 proteins, ACE2, TMPRSS2, and other protein targets. HCQ and CQ were not found to strongly interact with viral proteins, including its RNA polymerase, main protease, or ligand. However, five possible binding sites were discovered on the ACE2 receptor.